<?xml version="1.0" encoding="UTF-8"?>
<ref id="B50-pharmaceuticals-13-00096">
 <label>50.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Bolles</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Deming</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Long</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Agnihothram</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Whitmore</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Ferris</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Funkhouser</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Gralinski</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Totura</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Heise</surname>
    <given-names>M.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge</article-title>
  <source>J. Virol.</source>
  <year>2011</year>
  <volume>85</volume>
  <fpage>12201</fpage>
  <lpage>12215</lpage>
  <pub-id pub-id-type="doi">10.1128/JVI.06048-11</pub-id>
  <pub-id pub-id-type="pmid">21937658</pub-id>
 </element-citation>
</ref>
